Sequence: CPP-1:GKGKLRKRLK;CPP-2:KFFKFFKFFK;CPP-3:RRRRRRR;CPP-4:RKKRRQRRR;CPP-5:RKKRRQRRRPPQ;CPP-6:RKKRRQRRRPPQY;CPP-7:RRRRRRRRR;CPP-8:RGGRLSYSRRRFSTSTGR
| Experiment Id | EXP001072 |
|---|---|
| Paper | Designing siRNA for silencing the human ERBB2 gene in cancer treatment: Evaluating intracellular del |
| Peptide | LMWP CPP set (CPP-1..CPP-8) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | 8 peptides : 1 siRNA (as modeled) |
| Formulation Format | CPP-covered siRNA complex in DPPC:DPPG bilayer (CG simulation) |
| Formulation Components | Designed siRNA-3 covered by 8 LMWP CPPs; CG MARTINI model; DPPC:DPPG (3:1) bilayer; 500 ns traditional CG + steered CG pulling |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | |
| Animal Model | |
| Administration Route | |
| Output Type | Membrane interaction / stability (CG simulation) |
| Output Value | Less pulling force vs naked siRNA; complex remained bound to bilayer after 500 ns |
| Output Units | |
| Output Notes | Steered CG and traditional CG simulations only; no in vitro functional knockdown and no in vivo data. |
| Toxicity Notes | |
| Curation Notes |